GlassScriptPhysician profile
Long P Dang
NPI 1346324613
$83,148.29
in general payments reported to CMS, 2019-2025
21 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $9,168 · 2021: $4,206 · 2022: $8,170 · 2023: $6,110 · 2024: $17K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $2,919 · Travel and Lodging: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,710.00 |
| Food and Beverage | $2,919.09 |
| Travel and Lodging | $733.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,797.73 | 2019-2025 | Creon, Linzess, Viberzi |
| Gilead Sciences, INC. | $14,641.91 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $11,183.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,428.14 | 2019-2022 | |
| Allergan, INC. | $674.49 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $369.00 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $215.41 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $172.62 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $139.15 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.08 | 2019-2021 | |
| Braintree Laboratories, INC. | $101.06 | 2020-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $74.22 | 2023-2024 | Talicia |
| Boston Scientific Corporation | $51.18 | 2024 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Vivus LLC | $41.69 | 2021-2025 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $34.95 | 2021-2023 | Ocaliva |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.51 | 2023 | |
| Shionogi INC | $25.74 | 2019 | |
| Merck Sharp & Dohme LLC | $23.78 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.84 | 2025 | Pyrukynd |
| Micro-Tech Endoscopy USA, INC. | $7.36 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.